A novel multiple-stage antimalarial agent that inhibits protein synthesis
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3154657
Author(s) Baragana, Beatriz; Hallyburton, Irene; Lee, Marcus C. S.; Norcross, Neil R.; Grimaldi, Raffaella; Otto, Thomas D.; Proto, William R.; Blagborough, Andrew M.; Meister, Stephan; Wirjanata, Grennady; Ruecker, Andrea; Upton, Leanna M.; Abraham, Tara S.; Almeida, Mariana J.; Pradhan, Anupam; Porzelle, Achim; Santos Martinez, Maria; Bolscher, Judith M.; Woodland, Andrew; Norval, Suzanne; Zuccotto, Fabio; Thomas, John; Simeons, Frederick; Stojanovski, Laste; Osuna-Cabello, Maria; Brock, Paddy M.; Churcher, Tom S.; Sala, Katarzyna A.; Zakutansky, Sara E.; Belen Jimenez-Diaz, Maria; Maria Sanz, Laura; Riley, Jennifer; Basak, Rajshekhar; Campbell, Michael; Avery, Vicky M.; Sauerwein, Robert W.; Dechering, Koen J.; Noviyanti, Rintis; Campo, Brice; Frearson, Julie A.; Angulo-Barturen, Inigo; Ferrer-Bazaga, Santiago; Javier Gamo, Francisco; Wyatt, Paul G.; Leroy, Didier; Siegl, Peter; Delves, Michael J.; Kyle, Dennis E.; Wittlin, Sergio; Marfurt, Jutta; Price, Ric N.; Sinden, Robert E.; Winzeler, Elizabeth A.; Charman, Susan A.; Bebrevska, Lidiya; Gray, David W.; Campbell, Simon; Fairlamb, Alan H.; Willis, Paul A.; Rayner, Julian C.; Fidock, David A.; Read, Kevin D.; Gilbert, Ian H.
Author(s) at UniBasel Wittlin, Sergio
Year 2015
Title A novel multiple-stage antimalarial agent that inhibits protein synthesis
Journal Nature
Volume 522
Number 7556
Pages / Article-Number 315-+
Abstract

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

Publisher Macmillan
ISSN/ISBN 0028-0836
edoc-URL http://edoc.unibas.ch/dok/A6411079
Full Text on edoc No
Digital Object Identifier DOI 10.1038/nature14451
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/26085270
ISI-Number WOS:000356425400047
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.455 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
08/08/2020